BioCentury
ARTICLE | Finance

Polyneuron’s surgical strike

Why Sofinnova Partners, NEA backed Polyneuron's $22.6M series A

March 28, 2019 11:22 PM UTC

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A round.

Unlike therapies for autoimmune diseases that target B cells, Sofinnova’s Graziano Seghezzi told BioCentury that Polyneuron Pharmaceuticals AG’s approach could prevent immuno-depletion in patients and side effects. “They have a very surgical approach to take out only the autoantibody that is the culprit of the disease.”...